These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 20687622

  • 1. Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease.
    Croxtall JD, Scott LJ.
    Drugs; 2010 Aug 20; 70(12):1593-601. PubMed ID: 20687622
    [Abstract] [Full Text] [Related]

  • 2. Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief.
    Howden CW, Larsen LM, Perez MC, Palmer R, Atkinson SN.
    Aliment Pharmacol Ther; 2009 Nov 01; 30(9):895-907. PubMed ID: 19681809
    [Abstract] [Full Text] [Related]

  • 3. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis.
    Metz DC, Howden CW, Perez MC, Larsen L, O'Neil J, Atkinson SN.
    Aliment Pharmacol Ther; 2009 Apr 01; 29(7):742-54. PubMed ID: 19210298
    [Abstract] [Full Text] [Related]

  • 4. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation--results from two randomized controlled studies.
    Sharma P, Shaheen NJ, Perez MC, Pilmer BL, Lee M, Atkinson SN, Peura D.
    Aliment Pharmacol Ther; 2009 Apr 01; 29(7):731-41. PubMed ID: 19183157
    [Abstract] [Full Text] [Related]

  • 5. Dexlansoprazole MR: a review.
    Hershcovici T, Jha LK, Fass R.
    Ann Med; 2011 Aug 01; 43(5):366-74. PubMed ID: 21366513
    [Abstract] [Full Text] [Related]

  • 6. The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
    Peura DA, Pilmer B, Hunt B, Mody R, Perez MC.
    Aliment Pharmacol Ther; 2013 Apr 01; 37(8):810-8. PubMed ID: 23451835
    [Abstract] [Full Text] [Related]

  • 7. Dexlansoprazole for the treatment of esophagitis and GERD.
    Davies SL.
    Drugs Today (Barc); 2010 Feb 01; 46(2):75-80. PubMed ID: 20393635
    [Abstract] [Full Text] [Related]

  • 8. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.
    Fass R, Chey WD, Zakko SF, Andhivarothai N, Palmer RN, Perez MC, Atkinson SN.
    Aliment Pharmacol Ther; 2009 Jun 15; 29(12):1261-72. PubMed ID: 19392864
    [Abstract] [Full Text] [Related]

  • 9. Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.
    Emerson CR, Marzella N.
    Clin Ther; 2010 Aug 15; 32(9):1578-96. PubMed ID: 20974316
    [Abstract] [Full Text] [Related]

  • 10. Dexlansoprazole MR for the management of gastroesophageal reflux disease.
    Behm BW, Peura DA.
    Expert Rev Gastroenterol Hepatol; 2011 Aug 15; 5(4):439-45. PubMed ID: 21780890
    [Abstract] [Full Text] [Related]

  • 11. Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
    Peura DA, Pilmer B, Hunt B, Mody R, Perez MC.
    Aliment Pharmacol Ther; 2013 Nov 15; 38(10):1303-11. PubMed ID: 24118079
    [Abstract] [Full Text] [Related]

  • 12. Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.
    Abel C, Desilets AR, Willett K.
    Ann Pharmacother; 2010 May 15; 44(5):871-7. PubMed ID: 20371754
    [Abstract] [Full Text] [Related]

  • 13. Dual Delayed-Release Dexlansoprazole for Healing and Maintenance of Healed Erosive Esophagitis: A Safety Study in Adolescents.
    Gremse D, Gold BD, Pilmer B, Hunt B, Korczowski B, Perez MC.
    Dig Dis Sci; 2019 Feb 15; 64(2):493-502. PubMed ID: 30390234
    [Abstract] [Full Text] [Related]

  • 14. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
    Peura DA, Metz DC, Dabholkar AH, Paris MM, Yu P, Atkinson SN.
    Aliment Pharmacol Ther; 2009 Nov 15; 30(10):1010-21. PubMed ID: 19735233
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials.
    Vakily M, Zhang W, Wu J, Atkinson SN, Mulford D.
    Curr Med Res Opin; 2009 Mar 15; 25(3):627-38. PubMed ID: 19232037
    [Abstract] [Full Text] [Related]

  • 16. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results.
    Lauritsen K, Devière J, Bigard MA, Bayerdörffer E, Mózsik G, Murray F, Kristjánsdóttir S, Savarino V, Vetvik K, De Freitas D, Orive V, Rodrigo L, Fried M, Morris J, Schneider H, Eklund S, Larkö A, Metropole study results.
    Aliment Pharmacol Ther; 2003 Feb 15; 17(3):333-41. PubMed ID: 12562445
    [Abstract] [Full Text] [Related]

  • 17. Lansoprazole for maintenance of remission of erosive oesophagitis.
    Freston JW, Jackson RL, Huang B, Ballard ED.
    Drugs; 2002 Feb 15; 62(8):1173-84. PubMed ID: 12010078
    [Abstract] [Full Text] [Related]

  • 18. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
    Vakily M, Lee RD, Wu J, Gunawardhana L, Mulford D.
    Clin Drug Investig; 2009 Feb 15; 29(1):35-50. PubMed ID: 19067473
    [Abstract] [Full Text] [Related]

  • 19. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
    Scott LJ, Dunn CJ, Mallarkey G, Sharpe M.
    Drugs; 2002 Feb 15; 62(7):1091-118. PubMed ID: 11985491
    [Abstract] [Full Text] [Related]

  • 20. The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease.
    Fass R, Frazier R.
    Therap Adv Gastroenterol; 2017 Feb 15; 10(2):243-251. PubMed ID: 28203282
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.